Fractionated radioimmunotherapy with90Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer

Treatment of Advanced Pancreatic Carcinoma with 90Y-Clivatuzumab Tetraxetan: A Phase I Single-Dose Escalation Trial

(2011) S. A. Gulec et al.   CLINICAL CANCER RESEARCH

Cancer radioimmunotherapy

(2011) Robert M Sharkey et al.   Immunotherapy

Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial

(2011) Daniel D. Von Hoff et al.   JOURNAL OF CLINICAL ONCOLOGY

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Detection of Early-Stage Pancreatic Adenocarcinoma

(2010) D. V. Gold et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

High Rates of Durable Responses With Anti-CD22 Fractionated Radioimmunotherapy: Results of a Multicenter, Phase I/II Study in Non-Hodgkin's Lymphoma

(2010) Franck Morschhauser et al.   JOURNAL OF CLINICAL ONCOLOGY

Pancreatic Cancer

(2010) Manuel Hidalgo   NEW ENGLAND JOURNAL OF MEDICINE

Improving Gemcitabine-Mediated Radiosensitization Using Molecularly Targeted Therapy: A Review

(2008) M. A. Morgan et al.   CLINICAL CANCER RESEARCH

Evaluation of lymph nodes with RECIST 1.1

(2008) L.H. Schwartz et al.   EUROPEAN JOURNAL OF CANCER